Table 1.

Baseline characteristics of giant cell arteritis study patients.

CharacteristicsTAB+, n = 18TAB−, n = 10Overall, n = 28p
Age, yrs73.2 ± 8.165.4 ± 8.470.4 ± 8.90.024
Female, n (%)12 (67)5 (50)17 (61)0.39
Mean BMI, SD, kg/m229.4 ± 18.128.1 ± 6.928.9 ± 150.83
Mean systolic BP, mm/hg134 ± 13.6128 ± 12.4132 ± 13.30.27
Mean diastolic BP, mm/hg73.5 ± 9.575.3 ± 9.374.1 ± 9.30.63
Symptoms, n (%)
  Fever6 (33)1 (10)7 (25)0.51
  Weight loss8 (44)4 (40)12 (43)0.82
  Polymyalgia rheumatica8 (44)3 (30)11 (39)0.45
  Headache13 (72)9 (90)22 (79)0.27
  Visual7 (39)7 (70)14 (50)0.11
  Jaw claudication11 (61)4 (40)15 (54)0.28
  Scalp tenderness13 (72)9 (90)22 (79)0.27
  Chest pain1 (6)0 (0)1 (4)0.45
  Limb claudication2 (11)0 (0)2 (7)0.27
Laboratory variables, mean
  WBC, × 109/l10.2 ± 3.77.8 ± 3.29.3 ± 3.70.10
  Hemoglobin, g/l117 ± 18132 ± 9.7122 ± 170.022
  Platelet, × 109/l392 ± 160278 ± 79351 ± 1460.046
  ESR, mm/h78 ± 4247 ± 3666 ± 420.06
  CRP, mg/l112 ± 9535 ± 4584 ± 880.024
  Creatinine, mmol/l85 ± 3780 ± 1783 ± 310.70
  Length of biopsy specimen, cm2.7 ± 1.02.1 ± 0.92.5 ± 1.00.12
Medications, n (%)
  Aspirin or clopidogrel5 (28)2 (20)7 (25)0.65
  Statin5 (28)1 (10)6 (21)0.27
  Antihypertensive8 (44)4 (40)12 (43)0.82
  Prednisone18 (100)10 (100)28 (100)1.00
  Daily dose prednisone, mg55.6 ± 1251.5 ± 1354.1 ± 120.41
Cumulative prednisone, mg
  Prior to PET/CT603 ± 515720 ± 416645 ± 4770.54
  Prior to biopsy517 ± 438892 ± 807651 ± 6100.12
  • All values presented reflect the mean values ± SD unless otherwise stated. TAB: temporal artery biopsy; BMI: body mass index; BP: blood pressure; WBC: white blood cells; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PET/CT: positron emission tomography/computerized tomography.